Dental management of patients on anti-thrombotic agents

키워드

참고문헌 (46)

1. Vahanian A, "Guidelines on the management of valvular heart disease (version 2012): the joint task force on the management of valvular heart disease of the European society of cardiology (ESC) and the European association for cardio-thoracic surgery (EACTS)", Eur Heart J, 33, pp.2451~2496 (2012)[DOI]
2. Camm AJ, "Guidelines for the management of atrial fibrillation: the task force for the management of atrial fibrillation of the European society of cardiology (ESC)", Europace, 12, pp.1360~1420 (2010)[DOI]
3. Wolberg AS, "Procoagulant activity in hemostasis and thrombosis: Virchow's triad revisited", Anesth Analg, 114, pp.275~285 (2012)[DOI]
4. [URL]
5. Coleman RA, "Comprehensive medicinal chemistry: membranes and receptors", pp.643~714 (1990), Pergamon Press
6. Levine GN, "2011 ACCF", AHA, American heart association task force on practice guidelines and the society for cardiovascular angiography and interventions, pp.J Am Coll Cardiol, 2011[DOI]
7. Lange RA, "The duel between dual antiplatelet therapies", N Engl J Med, 368, pp.1356~1357 (2013)[DOI]
8. Biondi-Zoccai GG, "A systematic review and meta-analysis on the hazards of discontinuing or not adhering to aspirin among 50,279 patients at risk for coronary artery disease", Eur Heart J, 27, pp.2667~2674 (2006)[DOI]
9. Oscarsson A, "To continue or discontinue aspirin in the perioperative period: a randomized, controlled clinical trial", Br J Anesth, 104, pp.305~312 (2010)[DOI]
10. Dorsam RT, "Central role of the P2Y12 receptor in platelet activation", J Clin Invest, 113, pp.340~345 (2004)[DOI]
11. Cattaneo M, "Response variability to clopidogrel: is tailored treatment, based on laboratory testing, the right solution?", J Thromb Haemost, 10, pp.327~336 (2012)[DOI]
12. de Morais SM, "The major genetic defect responsible for the polymorphism of S-mephenytoin metabolism in humans", J Biol Chem, 269, pp.15419~15422 (1994)
13. Mega JL, "Cytochrome P450 genetic polymorphisms and the response to prasugrel: relationship to pharmacokinetic, pharmacodynamic, and clinical outcomes", Circulation, 119, pp.2553~2560 (2009)[DOI]
14. Birkeland K, "Antiplatelet therapy in acute coronary syndromes: focus on ticagrelor", J Blood Med, 1, pp.197~219 (2010)
15. Davi G, "Platelet activation and atherothrombosis", New Engl J Med, 357, pp.2482~2494 (2007)[DOI]
16. Furie B, "Mechanisms of thrombus formation", New Engl J Med, 359, pp.938~949 (2008)[DOI]
17. de Souza Brito F, "Novel anti-platelet agents: focus on thrombin receptor antagonists", J Cardiovasc Transl Res, 6, pp.415~424 (2013)[DOI]
18. [URL]
19. [URL]
20. [URL]
21. [URL]
22. [URL]
23. [URL]
24. Pollack CV Jr, "Idarucizumab for dabigatran reversal", N Engl J Med, 373, pp.511~520 (2015)[DOI]
25. Blommel ML, "Dabigatran etexilate: a novel oral direct thrombin inhibitor", Am J Health Syst Pharm, 68, pp.1506~1519 (2011)[DOI]
26. Eikelboom JW, "Dabigatran versus warfarin in patients with mechanical heart valves", N Engl J Med, 369, pp.1206~1214 (2013)[DOI]
27. Brown DG, "A review of traditional and novel oral anticoagulant and antiplatelet therapy for dermatologists and dermatologic surgeons", J Am Acad Dermatol, 72, pp.524~534 (2015)[DOI]
28. Armstrong MJ, "Summary of evidence-based guideline: periprocedural management of antithrombotic medications in patients with ischemic cerebrovascular disease: report of the guideline development subcommittee of the American academy of neurology", Neurology, 80, pp.2065~2069 (2013)[DOI]
29. Hsueh WD, "Perioperative management of antithrombotic therapy in common otolaryngologic surgical procedures: state of the art review", Otolaryngol Head Neck Surg, 153, pp.493~503 (2015)[DOI]
30. Connolly SJ, "Dabigatran versus warfarin in patients with atrial fibrillation", N Engl J Med, 361, pp.1139~1151 (2009)[DOI]
31. Patel MR, "Rivaroxaban versus warfarin in nonvalvular atrial fibrillation", N Engl J Med, 365, pp.883~891 (2011)[DOI]
32. Granger CB, "Apixaban versus warfarin in patients with atrial fibrillation", N Engl J Med, 365, pp.981~992 (2011)[DOI]
33. Lockhart PB, "Dental management considerations for the patient with an acquired coagulopathy. Part 1: coagulopathies from systemic disease", Br Dent J, 195, pp.439~445 (2003)[DOI]
34. Chan FKL, "Management of patients on antithrombotic agents undergoing emergency and elective endoscopy: joint Asian pacific association of gastroenterology (APAGE) and Asian pacific society for digestive endoscopy (APSDE) practice guidelines", Gut, 67, pp.405~417 (2018)[DOI]
35. McCormick NJ, "Haemostasis. Part 1: the management of post-extraction haemorrhage", Dent Update, 41, pp.290~ (2014)[DOI]
37. Napenas JJ, "Review of postoperative bleeding risk in dental patients on antiplatelet therapy", Oral Surg Oral Med Oral Pathol Oral Radiol, 115, pp.491~499 (2013)[DOI]
38. Douketis JD, "Perioperative management of antithrombotic therapy: antithrombotic therapy and prevention of thrombosis, 9th ed: American college of chest physicians evidence-based clinical practice guidelines", Chest, 141(2 Suppl), pp.e326~e350 (2012)[DOI]
39. Singer DE, "Antithrombotic therapy in atrial fibrillation: American college of chest physicians evidence-based clinical practice guidelines (8th edition)", Chest, 133(6 Suppl), pp.546S~592S (2008)[DOI]
40. [URL]
41. Nematullah A, "Dental surgery for patients on anticoagulant therapy with warfarin: a systematic review and meta-analysis", J Can Dent Assoc, 75, pp.41~ (2009)
42. British Medical Association, "British National Formulary (BNF) 70" (2015), BMJ Group, Pharmaceutical Press
43. Favaloro EJ, "The new oral anticoagulants and the future of haemostasis laboratory testing", Biochem Med (Zagreb), 22, pp.329~341 (2012)
44. Scaglione F, "New oral anticoagulants: comparative pharmacology with vitamin K antagonists", Clin Pharmacokinet, 52, pp.69~82 (2013)[DOI]
45. [URL]
46. [URL]

관련 논문AI추천